TD Cowen analyst Tyler Van Buren has maintained their bullish stance on TVTX stock, giving a Buy rating on February 14.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Tyler Van Buren has given his Buy rating due to a combination of factors that indicate strong future growth potential for Travere Therapeutics. The company reported significant quarter-over-quarter sales growth for its key drug, Filspari, which aligns with pre-announced expectations. This growth is supported by the increase in prescriptions and the expanded use of Filspari in treating patients with lower proteinuria levels, reflecting updated guidelines and labeling.
Additionally, the potential for further market expansion is evident with the anticipated submission of a supplemental New Drug Application (sNDA) for FSGS treatment, expected by the end of the first quarter. This submission could lead to an approval by the end of the year, providing another avenue for revenue growth. Furthermore, adjustments in guidelines and prescriber behavior, alongside updates in payor authorization criteria, underscore the drug’s growing importance in the market, supporting a positive outlook for Travere Therapeutics.
In another report released on February 14, Guggenheim also maintained a Buy rating on the stock with a $47.00 price target.